Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 31;15(7):2105.
doi: 10.3390/cancers15072105.

Precision Oncology Targets in Biliary Tract Cancer

Nicole Farha  1 , Danai Dima  2 , Fauzia Ullah  2 , Suneel Kamath  2
Affiliations
Review

Precision Oncology Targets in Biliary Tract Cancer

Nicole Farha et al. Cancers (Basel). .

Abstract

Targeted therapies in biliary tract cancer (BTC) are emerging as options for patients not who do not respond to first-line treatment. Agents acting on tumor-specific oncogenes in BTC may target fibroblast growth factor receptor 2 (FGFR2), isocitrate dehydrogenase (IDH), B-raf kinase (BRAF), and human epidermal growth factor receptor 2 (HER-2). Additionally, given the heterogeneous genetic landscape of advanced BTCs, many harbor genetic aberrations that are common among solid tumors, including RET fusions, tropomyosin receptor kinase (TRK) fusions, and high tumor mutational burden (TMB). This review aims to provide updates on the evolving array of therapeutics available, and to summarize promising works on the horizon.

Keywords: advanced stage; biliary cancer; cholangiocarcinoma; combination therapy; monotherapy; second line; targeted therapy; treatment resistant.

PubMed Disclaimer

Conflict of interest statement

N.F., D.D. and F.U. declare no conflict of interest. S.K. performs consulting and advisory roles for SeaGen, Exelixis, Tempus, Guardant Health, and Foundation Medicine.

Figures

Figure 1
Figure 1
Prevalence of genomic aberrations by anatomic classification in cholangiocarcinoma [91,102,103,104,105,106,107,108,109,110,111].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., et al. Cholangiocarcinoma 2020: The next Horizon in Mechanisms and Management. Nat. Rev. Gastroenterol. Hepatol. 2020;17:557–588. doi: 10.1038/s41575-020-0310-z. - DOI - PMC - PubMed
    1. Javle M., Lee S., Azad N.S., Borad M.J., Kate Kelley R., Sivaraman S., Teschemaker A., Chopra I., Janjan N., Parasuraman S., et al. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist. 2022;27:874–883. doi: 10.1093/oncolo/oyac150. - DOI - PMC - PubMed
    1. Kang M.J., Lim J., Han S.-S., Park H.M., Kim S.-W., Lee W.J., Woo S.M., Kim T.H., Won Y.-J., Park S.-J. Distinct Prognosis of Biliary Tract Cancer According to Tumor Location, Stage, and Treatment: A Population-Based Study. Sci. Rep. 2022;12:10206. doi: 10.1038/s41598-022-13605-3. - DOI - PMC - PubMed
    1. Yin L., Zhao S., Zhu H., Ji G., Zhang X. Primary Tumor Resection Improves Survival in Patients with Multifocal Intrahepatic Cholangiocarcinoma Based on a Population Study. Sci. Rep. 2021;11:12166. doi: 10.1038/s41598-021-91823-x. - DOI - PMC - PubMed
    1. Jarnagin W.R., Fong Y., DeMatteo R.P., Gonen M., Burke E.C., Bodniewicz J., Youssef M., Klimstra D., Blumgart L.H. Staging, Resectability, and Outcome in 225 Patients with Hilar Cholangiocarcinoma. Ann. Surg. 2001;234:507–519. doi: 10.1097/00000658-200110000-00010. - DOI - PMC - PubMed